Vir Biotechnology Announces Pricing of Public Offering of Common Stock
MWN-AI** Summary
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical firm dedicated to enhancing the immune system for treatments of serious infectious diseases and cancer, has announced the pricing of its underwritten public offering of 17,647,058 shares of common stock at $8.50 per share. The offering is expected to yield gross proceeds of approximately $150 million, before expenses and commissions are deducted. The company has also provided underwriters with a 30-day option to acquire an additional 2,647,058 shares at the public offering price.
The transaction is scheduled to close on February 27, 2026, pending customary conditions. Leading the offering are major firms including Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, and Barclays, who will serve as book-running managers. The offering is being conducted under an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023.
Vir Biotechnology, known for its innovative approach to biopharmaceuticals, has a diverse clinical portfolio addressing various health issues, including chronic hepatitis delta and oncology therapies that include the PRO-XTEN® dual-masked T-cell engagers. The company also maintains a pipeline of preclinical programs aimed at infectious diseases and cancers.
In the announcement, Vir Biotechnology included several forward-looking statements that highlight potential uncertainties regarding the offering's completion. The company reminds investors to consider various risk factors outlined in their Annual Report on Form 10-K submitted to the SEC on February 23, 2026. Despite the forward-looking nature of some statements, Vir Biotechnology aims to communicate transparently with its stakeholders.
MWN-AI** Analysis
Vir Biotechnology, Inc. (Nasdaq: VIR) recently announced the pricing of its public offering of 17,647,058 shares of common stock at $8.50 per share, aiming to raise $150 million before expenses. This move reflects the company’s intention to bolster its capital resources as it continues to navigate the clinical development of its innovative therapies targeting serious infectious diseases and cancer.
Investors should evaluate this offering against several market dynamics. Firstly, the biotechnology sector is known for its volatility, influenced by regulatory approvals, clinical trial results, and broader market sentiments. Vir's portfolio, which includes programs for chronic hepatitis delta and promising oncology therapies, underscores the potential for significant upside if these candidates proceed successfully through clinical trials. However, the inherent risks in developmental milestones must be taken into account.
The pricing of the offering at $8.50 is crucial; this is at a discount to recent trading levels, indicating potential short-term pressure on the stock price post-offering. Investors may experience dilution of current shares, which is a common consideration with public offerings. Thus, adopting a cautious stance may be advisable in the short term, especially given the market’s reaction to similar biotech offerings.
Furthermore, the backing by reputable underwriters such as Goldman Sachs and Barclays provides some assurance of market confidence in the offering, suggesting institutional interest may be present. Investors should also monitor the broader market conditions, as the biotech sector can be sensitive to shifts in investor sentiment and policy changes impacting healthcare.
In summary, while the public offering presents an opportunity for Vir Biotechnology to strengthen its financial position, investors should remain vigilant about potential risks and market reactions, balancing both the promise of innovative therapies and the realities of biotech investment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 17,647,058 shares of its common stock at a price to the public of $8.50 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Vir Biotechnology has granted the underwriters a 30-day option to purchase up to an additional 2,647,058 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being sold by Vir Biotechnology. Closing of the offering is expected to occur on February 27, 2026, subject to customary closing conditions.
Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI and Barclays are acting as book-running managers for the offering.
The shares described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission, or the SEC, on November 3, 2023. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on February 24, 2026. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, by contacting: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Evercore Group L.L.C., Attn: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847, or by email at Barclaysprospectus@broadridge.com; or by accessing the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “should,” “could,” “may,” “might,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the completion of the offering. Many factors may cause differences between current expectations and actual results, including, without limitation, risks and uncertainties related to the satisfaction of the customary closing conditions related to the offering. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on these forward-looking statements, which are based on Vir Biotechnology’s available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the section titled “Risk Factors” of Vir Biotechnology’s Annual Report on Form 10-K, filed with the SEC on February 23, 2026, and in the preliminary prospectus supplement relating to the offering. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260225619481/en/
Media
Caren Scannell
Director, Communications
cscannell@vir.bio
Investors
Kiki Patel, PharmD
Head of Investor Relations
kpatel@vir.bio
FAQ**
How will the proceeds from the public offering of Vir Biotechnology Inc. (Nasdaq: VIR) be utilized to advance its pipeline of infectious disease and cancer treatments?
What impact does Vir Biotechnology Inc. (VIR) expect from the potential exercise of the underwriters' 30-day option to purchase additional shares on the company's financial position?
Given the risks mentioned in the forward-looking statements, how is Vir Biotechnology Inc. (VIR) planning to mitigate uncertainties related to the completion of the public offering?
How does the clinical-stage portfolio of Vir Biotechnology Inc. (Nasdaq: VIR) align with broader trends in immunotherapy and biopharmaceutical research?
**MWN-AI FAQ is based on asking OpenAI questions about Vir Biotechnology Inc. (NASDAQ: VIR).
NASDAQ: VIR
VIR Trading
8.01% G/L:
$9.71 Last:
817,796 Volume:
$9.44 Open:
